Production and therapeutic use of off-the-shelf double negative t cells
AssigneeUniversity Health Network
InventorsLi Zhang, Jong Bok Lee, Hyeonjeong Kang
Life of this patent
Estimating the term…
Abstract
Described are methods for the production and use of cryopreservable double negative T cells (DNTs) for the treatment of cancer as an off-the-shelf cellular therapy. A sample population of DNTs is expanded using DNTs from one or more donors. The expanded population of DNTs from different donors does not exhibit alloreactivity against allogenic cells in the expanded population. The expanded populations of DNTs can be long-term stored as cryopreserved products.
Claims19
A method for cryopreserving double negative T cells (DNTs), the method comprising:
- a. providing a sample population of DNTs, wherein the sample population of DNTs comprises DNTs from one or more donors;
- b. culturing the sample population of DNTs in a culture comprising animal serum-free media supplemented with human plasma to produce an expanded population of DNTs;
- c. re-suspending the population of DNTs in a cryopreservation medium;
- d. adding DMSO to the cryopreservation medium to a final concentration of between about 3% and about 15% DMSO;
- and
- e. cryopreserving the population of DNTs in the cryopreservation medium at a temperature less than −70° C.
The population of DNTs of claim 13, wherein the DNTs comprise surface markers (a) CD11a+, CD18+, CD10−, and/or TCR Vα24−Jα18− and/or (b) CD49d+, CD45+,CD58+, CD147+, CD98+, CD43+, CD66b−, CD35−, CD36−, and/or CD103−.
Dependencies are inferred from the claim text.